Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US by Zafari, Zafar et al.
Zafari et al. Cost Eff Resour Alloc  (2018) 16:3 
https://doi.org/10.1186/s12962-018-0089-8
RESEARCH
Cost-effectiveness of tiotropium 
versus omalizumab for uncontrolled allergic 
asthma in US
Zafar Zafari1,2,3,4*, Mohsen Sadatsafavi2,3,4, J. Mark FitzGerald3,4 and for the Canadian Respiratory Research 
Network
Abstract 
Background: A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticoster-
oids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies 
(namely omalizumab) and more recently tiotropium bromide have been recommended for this subgroup of patients. 
The purpose of this study was to assess the cost-effectiveness of tiotropium versus omalizumab as add-on therapies 
to ICS + LABA for patients with uncontrolled allergic asthma.
Methods: A probabilistic Markov model of asthma was created. Total costs (in 2013 US $) and health outcomes of 
three interventions including standard therapy (ICS + LABA), add-on therapy with tiotropium, and add-on therapy 
with omalizumab, were calculated over a 10-year time horizon. Future costs and quality-adjusted life years (QALYs) 
were discounted at the rate of 3%. Multiple sensitivity analyses were conducted. Cost-effectiveness was evaluated at 
willingness-to-pay value of $50,000.
Results: The 10-year discounted costs and QALYs for standard therapy were $38,432 and 6.79, respectively. The corre-
sponding values for add-on therapy with tiotropium and with omalizumab were $41,535 and 6.88, and $217,847 and 
7.17, respectively. The incremental cost-effectiveness ratios (ICER) of add-on therapy with tiotropium versus standard 
therapy, and omalizumab versus tiotropium were $34,478/QALY, and $593,643/QALY, respectively. The model out-
comes were most sensitive to the costs of omalizumab but were robust against other assumptions.
Conclusions: Although omalizumab had the best health outcomes, add-on therapy with tiotropium was a cost-
effective alternative to omalizumab and standard therapy for uncontrolled allergic asthma at willingness-to-pay of 
$50,000/QALY.
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Background
A significant minority of asthma patients remain uncon-
trolled despite using a combination of inhaled corticos-
teroids (ICS) and long-acting beta-agonists (LABA). The 
burden of such uncontrolled asthma on the patient and 
society is high [1–4]. A number of novel therapeutic 
interventions for this sub-group of asthma patients have 
been developed, with improvement in asthma symptoms 
and a reduction in exacerbations documented in clini-
cal trials [5, 6]. The earliest example of such a targeted 
treatment is omalizumab. Omalizumab is an anti-IgE 
monoclonal antibody that has been approved for treat-
ing adults with 12  year and older with severe allergic 
asthma [7]. The addition of omalizumab to standard 
ICS + LABA therapy has been shown to have a positive 
effect on health outcomes and in particular a reduction in 
the rate of asthma exacerbations [8]. Recently, tiotropium 
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bromide has been shown to reduce the risk of asthma 
exacerbations when added to combination therapy [9, 10] 
and has subsequently received regulatory approval as an 
add-on therapy for the treatment of uncontrolled asthma 
[6]. Both treatments have been recommended at level 5 
in the GINA asthma treatment continuum [11].
Given the constrained healthcare resources, in addition 
to treatment effectiveness, the resources that are required 
for a treatment should also be considered to maximize 
population health. There have been a number of studies 
evaluating both the cost and effectiveness of add-on ther-
apy with omalizumab versus standard therapy in different 
settings [3, 12–17]. Willson et  al. have recently stud-
ied the cost-effectiveness of tiotropium compared with 
standard therapy in the UK [10, 18]. However, to the best 
of our knowledge, no single study has compared all the 
three alternatives in a unified framework. Without such a 
study, patients, clinicians, and policy makers do not have 
sufficient evidence on the choice of optimal therapy.
The aim of the present study was to use an evidence-
informed modeling approach to assess the health and 
economic consequences of the three strategies of con-
tinuation of standard therapy, add-on therapy with tio-
tropium, and add-on therapy with omalizumab for the 
treatment of uncontrolled allergic asthma.
Methods
Model
We developed a probabilistic Markov model of asthma to 
project the costs and quality-adjusted life years (QALYs) 
of patient with uncontrolled allergic asthma under differ-
ent treatments over 10 years. The setting for this evalua-
tion is patients with severe allergic asthma in the US, and 
the study adopts a US societal perspective. As such, in 
the main analysis both direct and indirect medical costs 
were included. The choice of time horizon was in line 
with the similar cost-effectiveness studies in uncontrolled 
asthma [15]. Three interventions were modeled: continu-
ation of standard therapy (high dose ICS + LABA), add-
on therapy with tiotropium, and add-on therapy with 
omalizumab. The model consisted of seven health states 
including three asthma control states (controlled, par-
tially controlled, uncontrolled), three exacerbation states 
(non-severe exacerbations, severe exacerbations without 
hospitalizations, and severe exacerbations requiring hos-
pitalizations), and a death state. The cycle length of the 
study was 1 week. Previous studies that assessed the cost-
effectiveness of omalizumab focused mainly on modelling 
the effect of treatment on transitioning between exacer-
bation free to exacerbation states [2, 3]. However, treat-
ments can also result in improved symptom control. To 
enable a more comprehensive modeling of the treatment 
effects on both control and exacerbation states, we built 
our model structure in line with the previously published 
model of tiotropium, which modeled transition across 
both control levels and exacerbation states [10]. In par-
ticular, definition of heath states in our study were in line 
with the PrimoTinA-asthma trials [6] and the previously 
published cost-effectiveness study of tiotropium [10]. 
The control states represent the degree of severity of the 
daily symptoms of the disease. Non-severe exacerbations 
are defined as worsening of patient’s daily symptoms over 
and beyond the normal variations in the current level of 
symptom control. Severe exacerbations without hospitali-
zations represent a need for an oral corticosteroids use or 
doubling the doses of daily medications, and hospitaliza-
tions represent an episode of exacerbation that requires 
inpatient care [6]. Figure 1 represents the model structure. 
This probabilistic model enabled the projection of costs, 
QALYs, and total number of exacerbations for the three 
interventions under the study. All the future costs and 
QALYs were discounted at 3%.
Parameters
Multiple outcome variables from published research 
were used to inform the model parameters, which are 
presented in Table  1. Model parameters were assigned 
probability distributions based on the degree of uncer-
tainty reported by the original studies. The transition 
probabilities for moving between different health states 
for the standard therapy and add-on therapy with tiotro-
pium were derived from a recent study by Willson et al. 
[18]. We could not find transition probabilities between 
the same health states for omalizumab in the published 
literature. Published research has mostly focused on the 
impact of omalizumab on the reduction of exacerbations 
as well as QALY gained [8, 19]. Thereby, using these data 
and the same methodology as in our earlier publications, 
we back-calculated the transition probabilities across 
different health states [4]. The details of this analysis are 
presented in the Additional file 1: Appendix 1.
Treatment costs were derived from previously pub-
lished US-based studies [2, 3]. We derived the costs of 
standard therapy from a study by Campbell et  al. [3]. 
These costs have been estimated from samples with a mix 
of asthma control levels. We estimated the costs per lev-
els of control based on the frequency of asthma control 
in the study sample and the evidence on the ratio of costs 
across control states [20]. The details of these calcula-
tions are shown in the Additional file 1: Appendix 2. The 
additional costs of omalizumab and tiotropium, as well as 
exacerbations costs were derived from the published lit-
erature [2, 3, 10, 21, 22]. All costs were adjusted to 2013 
US dollars, details of which can be found in Table 1.
The health state utility values (utilities) were derived 
from a recently published study by Willson et al. [10]. The 
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EQ-5D scores for the control states were estimated from 
the PrimoTinA-asthma trials and were converted into the 
utility values using the UK EuroQol tariff [10, 23]. The 
utility values for exacerbations states were derived from 
two recent studies by Willson et al. and LIoyd et al. [10, 
24]. The details of these values and their probabilistic dis-
tributions are shown in Table 1.
Analysis
We performed a main (base case) analysis by running 
the model with the point estimates of each parameter. 
Cost-effectiveness was interpreted around the reference 
willingness-to-pay (WTP) value of $50,000/QALY. A 
Monte-Carlo simulation with 10,000 runs was used to 
quantify uncertainty around the base case results. In each 
Monte Carlo run, a random sample was drawn from each 
distribution. From the results of the probabilistic analysis, 
we calculated 95% credible intervals (CrI) around point 
estimates of model outputs. We also generated the cost-
effectiveness plane and the cost-effectiveness accept-
ability curve. The former is a scatterplot representing the 
joint distribution of the difference in costs and QALYs 
between the add-on therapies. The latter represents the 
possibility of each of the three treatments being cost-
effective at different WTP values. The model was imple-
mented in statistical programming language R (version 
3.2.2) [25].
Sensitivity analysis
To investigate the robustness of the outcomes with 
respect to changes in core model parameters, we per-
formed a series of sensitivity analyses. The parameters 
evaluated were time horizon (changed to life time), base-
line age (changed from 20 to 60  years), discount rate 
Fig. 1 Markov model. States include controlled, partially controlled, uncontrolled, non-severe exacerbation, severe exacerbation without hospitali-
zation, and hospitalization
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(0–5%), cost of omalizumab (changed by ±  25%), cost 
of tiotropium (changed by ±  25%), health state costs 
(changed by ±  25%), utilities (changed by ±  10%), and 
30-day probability of death from severe asthma exacerba-
tions (changed from 0.01 to 0.03).
Results
Table  2 represents the results of the main analysis. For 
standard therapy, the total discounted 10-year costs 
and QALYs per person were $38,432 (95% CrI $32,075–
$48,657), and 6.79 (95% CrI 6.63–6.96), respectively. 
The corresponding values for add-on therapy with tio-
tropium and with omalizumab were $41,535 (95% CrI 
$35,034–$54,699) and 6.88 (95% CrI 6.69–7.07), and 
$217,847 (95% CrI $214,477–$224,863) and 7.17 (95% 
CrI 6.99–7.37), respectively. The ICER of add-on therapy 
with tiotropium versus standard therapy was $34,478/
QALY. The ICER of add-on therapy with omalizumab 
versus tiotropium was $593,643/QALY. The total num-
ber of exacerbations over 10  years per person was 
33 for standard therapy, 24 for tiotropium and 18 for 
omalizumab.
The results of the probabilistic analysis are presented 
in the Fig. 2. Figure 2a shows the cost-effectiveness plane 
for add-on therapy with omalizumab versus tiotropium. 
As seen in this figure, in the majority of the model runs, 
omalizumab had a higher effectiveness but also substan-
tially higher costs compared with tiotropium (thereby 
lying mostly within the north-east quadrant of the cost-
effectiveness plane). Figure  2b shows the cost-effective-
ness acceptability curve. The probability that standard 
therapy would be the best option compared to the other 
two alternatives was 45% at WTP of $50,000/QALY, 
and 34% at WTP of $100,000/QALY. The corresponding 
probabilities for add-on therapy with tiotropium were 
55% and 66%.
Table 1 Model Parameters
All costs are adjusted to 2013 US dollars using US consumer price index [22]
Gamma(x, y) distribution with shape parameter x, and rate parameter y, Beta(x, y) beta distribution with shape1 parameter x, and shape2 parameter y
a Details in the (Additional file 1: Appendix-1)
Parameters Value Probability distribution
Baseline age 40 –
Background mortality rate [30] US life tables –
Monthly chance of death from hospitalization [31] 0.0248 Beta(1.099, 43.224)
Direct cost (2013-$US) [2, 3]
Standard therapy costs (per person week)a
 Controlled $46 –
 Partially controlled $47 –
 Uncontrolled $53 –
Treatment costs (per person week) [2, 3, 10, 21, 22]
 Tiotropium $13 –
 Omalizumab $437 –
Cost of exacerbations (per person week) [2, 3]
 Non-severe exacerbation $130 Gamma(100, 0.77)
 Severe exacerbation without hospitalization $594 Gamma(98.01, 0.17)
 Hospitalization $9900 Gamma(100.08, 0.01)
Indirect cost (per person week) (used only for sensitivity analysis) [1, 4, 22]
 Controlled $165 –
 Partially controlled $185 –
 Uncontrolled $312 –
 Exacerbation (Including not severe exacerbation, severe exacerbation and hospitalization) $856 –
Health state utility values [10, 21, 22]
 Controlled 0.937 Beta(982.3883, 66.0517)
 Partially controlled 0.907 Beta(378.5135, 38.8112)
 Uncontrolled 0.728 Beta(1212.6010, 453.0598)
 Non-severe exacerbation 0.649 Beta(1243.7040, 672.6349)
 Severe exacerbation without hospitalization 0.570 Beta(1175.3160, 886.6418)
 Hospitalization 0.330 Beta(613.7850, 1246.1690)
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Figure  3 shows the results of the sensitivity analy-
ses. Changes in the cost of omalizumab had the great-
est impact on outcomes. Reducing cost of omalizumab 
by 25% would  decrease its ICER relative to tiotropium 
from  the base case value to $436,944/QALY. In addi-
tion,  increasing the cost of omalizumab by 25% would 
increase its base case ICER to $753,214/QALY relative to 
tiotropium. Changes in the other variables did not signif-
icantly alter the outcomes.
Discussion
In this study, we compared the cost-effectiveness of three 
treatment strategies for uncontrolled allergic asthma. 
Our study indicated that add-on therapy with tiotro-
pium was associated with an ICER of $34,478/QALY 
relative to standard therapy over a 10-year horizon. In 
contrast, add-on therapy with omalizumab had an ICER 
of $593,643/QALY relative to tiotropium. Therefore, the 
addition of tiotropium would be considered cost-effective 
compared to the other two alternatives at the convention-
ally used WTP of $50,000/QALY. Omalizumab showed 
the highest effectiveness both in terms of improvement 
in QALYs and reduction in the number of exacerbations, 
but this came with substantial incremental costs.
A number of studies have compared the costs and 
health outcomes of different treatments for uncon-
trolled asthma. Willson et al., whose model was adopted 
for this analysis, have reported on the cost-effectiveness 
of add-on therapy with tiotropium relative to standard 
therapy in the UK [10, 18]. Other studies have previously 
Table 2 The expected values and 95% CrI of model outcomes over 10 years
CrI credible interval, QALY quality-adjusted life year, ICER Incremental cost-effectiveness ratio
Outcome Standard therapy Tiotropium Omalizumab
Cost (95% CrI) $38,432 ($32,075–$48,657) $41,535 ($35,034–$54,699) $217,847 ($214,477–$224,863)
QALYs (95% CrI) 6.79 (6.63–6.96) 6.88 (6.69–7.07) 7.17 (6.99–7.37)
Number of weeks with non-severe exacerbations (95% CrI) 20.04 (15.90–24.64) 14.53 (11.07–18.87) 9.92 (7.34–12.91)
Number of weeks with severe exacerbations without hospi-
talization (95% CrI)
11.39 (7.21–16.16) 8.22 (5.03–11.97) 7.15 (4.14–10.94)
Number of hospitalizations (95% CrI) 1.10 (0.45–2.19) 1.05 (0.31–2.46) 0.54 (0.14–1.48)
ICER
 Tiotropium versus standard therapy Reference $34,478/QALY –
 Omalizumab versus tiotropium – Reference $593,643/QALY
 Omalizumab versus standard therapy Reference – $463,605/QALY
Fig. 2 a Cost-effectiveness plane for add-on therapies with omalizumab versus tiotropium. b Cost-effectiveness acceptability curve for standard 
therapy, and add-on therapies with tiotropium and omalizumab
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assessed the cost-effectiveness of add-on therapy with 
omalizumab versus standard therapy [3, 12–17]. None-
theless, the cost-effectiveness comparison of an add-on 
therapy with tiotropium and omalizumab has not, to our 
knowledge, previously been assessed. This comparison 
is required for decision makers and stakeholders to base 
their treatment decision on an objective framework. The 
data reported in this study have therefore important clin-
ical and policy implications.
There are some limitations in the present study. Stud-
ies of tiotropium in asthma have recruited both allergic 
and non-allergic asthma patients. By using evidence from 
such trials we assumed the same health benefits of tio-
tropium for allergic and non-allergic asthma patients. 
This assumption seems to be supported by the evidence 
in a post hoc analysis of the pivotal trials of tiotropium, 
that showed no difference between allergic versus non 
allergic subjects [26]. Unlike for tiotropium, we could 
not find any published transition probabilities for omali-
zumab across the seven health states used in this study 
[10, 18]. However, the lack of direct evidence should not 
preclude us from an objective evaluation of decisions 
that practitioners and policy makers currently face [27, 
28]. To overcome this evidential gap, we used accept-
able mathematical techniques to back-calculate these 
transition probabilities using the available evidence on 
treatment effect on exacerbation rates. Our calculations 
showed excellent internal validity, and the calculated 
ICER for omalizumab versus standard therapy is within 
the range of published ICERs [2, 3]. Ideally, future studies 
would directly compare the effect of tiotropium against 
omalizumab.
Conclusions
In summary, this study provides evidence on the direct 
comparison of the health and economic outcomes associ-
ated with competing treatment options for uncontrolled 
allergic asthma patients who are not controlled with cur-
rently available inhaled therapies. Asthma outcomes have 
significantly improved over the past decades [29]. How-
ever, a significant minority of patients remains sympto-
matic despite conventional therapies and contributes a 
significant burden to the health care system. While the 
emerging novel therapies for asthma present exciting 
Fig. 3 One-way sensitivity analysis: omalizumab versus tiotropium
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new treatment options, it is important to critically assess 
the cost-effectiveness of such treatments.
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